A perspective on the use of concentration-QT modeling in drug development
J Clin Pharmacol
.
2008 Jan;48(1):9-12.
doi: 10.1177/0091270007311115.
Authors
Tanya Russell
1
,
Steven P Riley
,
Jack A Cook
,
Richard L Lalonde
Affiliation
1
Clinical Pharmacology, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA.
PMID:
18094215
DOI:
10.1177/0091270007311115
No abstract available
Publication types
Comment
MeSH terms
Dose-Response Relationship, Drug
Drugs, Investigational / adverse effects*
Guidelines as Topic
Humans
Long QT Syndrome / chemically induced*
Long QT Syndrome / diagnosis
Risk Assessment / methods
Substances
Drugs, Investigational